Farmacia y Tecnología Farmacéutica

URI permanente para esta comunidadhttps://hdl.handle.net/11441/11019

Examinar

Examinando Farmacia y Tecnología Farmacéutica por Agencia financiadora "Academy of Medical Sciences"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 2 de 2
  • Miniatura
    Acceso AbiertoArtículo
    Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development
    (Multidisciplinary Digital Publishing Institute (MDPI), 2023) Simón, Jon Ander; Utomo, Emilia; Pareja, Félix; Collantes, María; Quincoces, Gemma; Otero, Aarón; Ecay, Margarita; Domínguez Robles, Juan; Larrañeta, Eneko; Peñuelas, Iván; Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica; Academy of Medical Sciences; Ministerio de Ciencia e Innovación (MICIN). España
    The use of intranasal implantable drug delivery systems has many potential advantages for the treatment of different diseases, as they can provide sustained drug delivery, improving patient compliance. We describe a novel proof-of-concept methodological study using intranasal implants with radiolabeled risperidone (RISP) as a model molecule. This novel approach could provide very valuable data for the design and optimization of intranasal implants for sustained drug delivery. RISP was radiolabeled with 125I by solid supported direct halogen electrophilic substitution and added to a poly(lactide-co-glycolide) (PLGA; 75/25 D,L-Lactide/glycolide ratio) solution that was casted on top of 3D-printed silicone molds adapted for intranasal administration to laboratory animals. Implants were intranasally administered to rats, and radiolabeled RISP release followed for 4 weeks by in vivo non-invasive quantitative microSPECT/CT imaging. Percentage release data were compared with in vitro ones using radiolabeled implants containing either 125I-RISP or [125I]INa and also by HPLC measurement of drug release. Implants remained in the nasal cavity for up to a month and were slowly and steadily dissolved. All methods showed a fast release of the lipophilic drug in the first days with a steadier increase to reach a plateau after approximately 5 days. The release of [125I]I− took place at a much slower rate. We herein demonstrate the feasibility of this experimental approach to obtain high-resolution, non-invasive quantitative images of the release of the radiolabeled drug, providing valuable information for improved pharmaceutical development of intranasal implants.
  • Miniatura
    Acceso AbiertoArtículo
    Solid Implantable Devices for Sustained Drug Delivery
    (Elsevier, 2023) Magill, Elizabeth; Demartis, Sara; Gavini, Elisabetta; Permana, Andi Dian; Thakur, Raghu Raj Singh; Adrianto, Muhammad Faris; Waite, David; Glover, Katie; Picco, Camila J.; Korelidou, Anna; Domínguez Robles, Juan; Larrañeta, Eneko; Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica; Academy of Medical Sciences; Engineering and Physical Sciences Research Council (UK); European Union (UE). H2020; Ministerio de Ciencia e Innovación (MICIN). España
    Implantable drug delivery systems (IDDS) are an attractive alternative to conventional drug administration routes. Oral and injectable drug administration are the most common routes for drug delivery providing peaks of drug concentrations in blood after administration followed by concentration decay after a few hours. Therefore, constant drug administration is required to keep drug levels within the therapeutic window of the drug. Moreover, oral drug delivery presents alternative challenges due to drug degradation within the gastrointestinal tract or first pass metabolism. IDDS can be used to provide sustained drug delivery for prolonged periods of time. The use of this type of systems is especially interesting for the treatment of chronic conditions where patient adherence to conventional treatments can be challenging. These systems are normally used for systemic drug delivery. However, IDDS can be used for localised administration to maximise the amount of drug delivered within the active site while reducing systemic exposure. This review will cover current applications of IDDS focusing on the materials used to prepare this type of systems and the main therapeutic areas of application.